Oligogen
Latest round
- Series A
Last raised
- Aug 2017
Total raised
- $1M
Investors
- 4
About Oligogen
Based in Kyoto, Japan, Oligogen, Inc.Founded in 2015 in Kyoto, Japan, Oligogen, Inc. specializes in developing therapies for neurological disorders. The company has undergone no major pivots in its strategy or operations and has not reported any subsidiaries.Oligogen Inc. specializes in advanced regenerative medicine aimed at treating neurological disorders through innovative therapies. The company's core product offerings include cell therapy utilizing their proprietary neural stem cell technology, Oligogeny, and exosome therapy targeting conditions such as Alzheimer's disease and multiple sclerosis. These therapies leverage biotechnology and genetic research to provide customized treatments with minimal side effects, addressing unmet medical needs in neurodegenerative diseases. The end users of Oligogen's products primarily consist of healthcare providers and institutions involved in treating severe neurological conditions, with a growing commitment to collaborating with universities and pharmaceutical companies globally for research and development efforts.Oligogen Inc. generates revenue through partnerships with academic institutions and pharmaceutical companies, along with direct collaborations with healthcare providers. Their business model emphasizes B2B transactions, focusing on supplying innovative therapies to hospitals and clinics specializing in neurology. Pricing structures and financial arrangements connected to their flagship products, such as the Oligogeny stem cell treatment and proprietary exosome formulations, reflect the high-value nature of advanced regenerative therapies. These transactions are typically negotiated on a case-by-case basis, aligning with the customized nature of the treatments.Oligogen, Inc. The company is working on new product designs, particularly focusing on novel exosome therapies, although specific release dates have not been disclosed. In terms of market expansion, Oligogen aims to increase its presence in North America and Europe by 2025, targeting collaborations with more healthcare institutions and pharmaceutical partners. Through these initiatives, Oligogen seeks to broaden access to its innovative medical solutions and improve treatment outcomes for patients with neurological disorders.
Who invested in Oligogen
4 investors across 1 round
See all investors in Oligogen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 1, 2017
Amount
$1M
Investors
Questions about Oligogen
Who invested in Oligogen?
Oligogen has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Oligogen raised?
Oligogen has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Oligogen last raise money?
Oligogen's most recent round on record is a Series A, in Aug 2017.
What does Oligogen do?
Based in Kyoto, Japan, Oligogen, Inc.
Where is Oligogen headquartered?
Oligogen is headquartered in Kyoto, Japan.
Which VCs invest in companies like Oligogen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Oligogen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Oligogen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.